PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Next Generation Sequencers Emerging as Indispensable Tools in Global Biomedical Research Finds Frost & Sullivan - Next generation sequencers (NGS) are penetrating into the service providing sector and the global biomedical research community where they are increasingly being identified as indispensable tools
Next Generation Sequencers Emerging as Indispensable Tools in Global Biomedical Research Finds Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2011/04/04 - Next generation sequencers (NGS) are penetrating into the service providing sector and the global biomedical research community where they are increasingly being identified as indispensable tools.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Recent scientific discoveries that are an outcome of next generation sequencing technology show the impact of massively parallel platforms. The declining cost of genomic sequencing has paved way for the clinical application of this technology. The tremendous growth in drug discovery and molecular diagnostics will promote the uptake of this technology.

New analysis from Frost & Sullivan (pharma.frost.com), European Next Generation Sequencing Markets, finds that the markets earned revenues of $278.3 million in 2010 and estimates this to reach $1,042.2 billion in 2017 due to the increased focus on human genome sequencing and the application of this technology to disease prediction. The segments covered include sequencing within the service providing sector and academic research laboratories.

"NGS are rapidly replacing microarray technology in key applications," notes Frost & Sullivan Research Analyst Divyaa Ravishankar. "Enhanced breadth of application is contributing, in turn, to wider coverage even as increased read lengths are being worked on in the new platforms."

The urge to sequence complex and variable human genomes has created opportunities for the growth of next generation sequencing in areas like gene discovery, gene expression, gene regulation studies and clinical diagnostic applications in Europe.

An increasing number of laboratories in Europe are replacing microarrays with NGS. Ongoing cancer research programmes, biomarker discovery, forensics and many funded drug discovery projects rely on NGS. Around 130 research centres in Europe are using this technology.

However, funding and technology related issues remain areas of concern. European research organisations are dependent on funding and grants. These are sometimes in short supply, posing problems for continued research. At the same time, technology overlapping by various NGS vendors raises IP concerns.

"There is significant concern regarding technology overlap since all the market participants have common goals that include sample preparation methods, higher throughput and cost-cutting measures," explains Ravishankar. "Competitors are moving towards longer reads and single molecule real-time sequencing (SMRT) and hence, the need to patent their technology is becoming a key issue."

Increase in the volume of data requiring efficient data management systems poses a challenge. At the same time, interpretation of complex data from next-generation platforms looms as another challenge that market participants and end users will need to tackle.

Applications for next generation sequencing can be better addressed with a multidisciplinary approach that embraces novel solutions and innovative technologies. Developing instruments that will cater to end-user needs will enable market participants to gain an edge.

"Concentrating on factors like greater read lengths, higher throughput and improved accuracy will help companies succeed," concludes Ravishankar. "Instrument pricing can also help promote sales."

For more information on this study, please send your complete contact details to Chiara Carella, Corporate Communications, at chiara.carella[.]frost.com.

European Next Generation Sequencing Markets is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European DNA Microarray Market and European Cancer Support Therapies Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

European Next Generation Sequencing Markets / M691

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Next Generation Sequencers Emerging as Indispensable Tools in Global Biomedical Research Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Chiara Carella 
+44 (0) 20 7343 8314 chiara.carella[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)